The invention relates to a process for preparing cellular microcompartments comprising a hydrogel capsule surrounding a cluster of lymphomatous cells. The invention also relates to such a cellular microcompartment and the use thereof for screening anti-cancer molecules.

The present invention solves the following problems [1] to [3] found in conventional methods of preparing a three dimensional structure (organ primordium) by coculturing functional cells with umbilical cord-derived vascular endothelial cells and bone marrow-derived mesenchymal cells: [1] the quality of resultant organ primordia varies greatly depending on donors; [2] the growth capacities of cell sources are limited; and [3] it is difficult to secure immunocompatibility because cells are derived from different sources. An organ bud prepared from vascular cells, mesenchymal cells and tissue or organ cells, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells. A method of preparing an organ bud, comprising culturing vascular cells, mesenchymal cells and tissue or organ cells in vitro, wherein each of the vascular cell, the mesenchymal cell and the tissue or organ cell has been induced from pluripotent stem cells.

The current invention concerns a cell medium for in vitro inducing chondrogenesis or tenogenesis in mesenchymal stem cells (MSCs). The medium includes a glucose medium supplemented with at least one growth factor. The growth factor is selected from fibroblast growth factors (FGF) or transforming growth factors (TGF). FGF or TGF is present in a total concentration of between 1 and 15 ng/ml. In both cases, IGF can be added to enhance the induction process. In a further aspect, the invention provides for a use of such cell medium as well as a method for inducing isolated mesenchymal stem cells (MSCs) and a cell composition obtained by such method.

An artificial tissue containing pancreatic islet cells, fibroblasts and/or cells capable of differentiating, extracellular matrix, and vascular endothelial cells, in which the fibroblasts and/or the cells capable of differentiating, the extracellular matrix, and the vascular endothelial cells constitute a three-dimensional tissue structure in which a vascular network structure has been formed, and in which the three-dimensional tissue structure contains pancreatic islets constituted by aggregating ten or more of the pancreatic islet cells.

Methods of implanting therapeutic cells in a subject and methods of preparing pancreatic islet cells for implantation into a subject, prior to implantation into a subject, are provided herein.

Stem cell conditioned media and methods of producing the same to treat mammalian injuries or insults. In at least one embodiment of a method of producing a stem cell conditioned media of the present disclosure, the method comprises the steps of culturing at least one stem cell in a first cell culture medium, replacing some or all of the first cell culture medium with a second cell culture medium and further culturing the at least one stem cell in the second cell culture medium, and collecting a quantity of the second cell culture medium after a culture duration, wherein the quantity of the second cell culture medium contains a cell culture byproduct effective to treat a mammalian insult or injury. A stem cell culture supernatant containing at least one factor capable of exerting effective neuroprotection to treat a mammalian neural injury or insult.

A CD7.sup.+ progenitor T cell, a method of producing the CD7.sup.+ progenitor T cell, and a method of administering the CD7.sup.+ progenitor T cell. The method of producing the CD7.sup.+ progenitor T cell includes expanding CD34.sup.+ cells.

An ex vivo generated population of tissue-specific alternatively-activated macrophages and methods of making and using such macrophages for treating orthopedic injury are provided.

Disclosed are methods of preparing CD34+CD43+ hematopoietic progenitor cells (HPC) in vitro according to embodiments of the invention. Also disclosed are methods of differentiating CD34+CD43+ hematopoietic progenitor cells to hematopoietic lineage cells according to embodiments of the invention. Also disclosed are methods of treating or preventing a condition in a mammal, e.g., cancer, according to embodiments of the invention.

Methods for generating enucleated erythroid cells using pluripotent stem cells are provided. The methods permit the production of large numbers of cells. The cells obtained by the methods disclosed may be used for a variety of research, clinical, and therapeutic applications. Methods for generating megakaryocyte and platelets are also provided.